NW 4 706
Alternative Names: NW-4-706Latest Information Update: 25 Aug 2023
At a glance
- Originator Newave Pharmaceuticals
- Developer Guangzhou Lupeng Pharmaceutical; Newave Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 20 Jul 2023 Early research in Haematological malignancies in USA, China (Guangzhou Lupeng Pharmaceutical pipeline, July 2023)